Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District

Objective : analyzing the acquisition and monthly costs for patients on modern fixed-dose antihypertensive combinations in three regions of Far Eastern Federal District. Material methods . Intra-group analysis retail drugs 2019 drugstores Khabarovsk Region, Sakhalin Amur Region (n=100) was carried out. The calculation cost therapy performed total sales indicators were identified. Statistical analysis: dispersion analysis, Spearman's rank correlation coefficient, Kruskal–Wallis test. Results maximum demand among -blockers price range 100-500 rubles: atenolol+chlortalidone; bisoprolol+amlodipine. In grope angiotensin-converting enzyme inhibitors with diuretics/calcium channel blockers, most often acquired were: perindopril/ramipril+indapamide/amlodipine, enalapril+hydrochlorothiazide – segment 500–1000 rubles. Preferences use angiotensin II receptor blockers+diuretic/calcium blockers: valsartan+amlodipine a 300–500 rubles; losartan+hydrochlorothiazide 100–500 rubles azilsartan+chlortalidonee popular three-component valsartan+amlodipine+hydrochlorothiazide, perindopril+amlodipine+indapamide over 500 Differences structure between statistically significant. Conclusion share combined remains insignificant. main selection criteria within an international nonproprietary name are affordability or trust brand. presence reliable region proves influence regional preferences specialists drug prescribing.